FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 336:404-409 February 6, 1997 Number 6 Next

	Full Text PDF Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background Polyethylene glycol (PEG)–conjugated recombinant human megakaryocyte growth and development factor (MGDF, also known as PEG-rHuMGDF), a recombinant molecule related to thrombopoietin, specifically stimulates megakaryopoiesis and platelet production and reduces the severity of thrombocytopenia in animals receiving myelosuppressive chemotherapy.

Methods We conducted a randomized, double-blind, placebo-controlled dose-escalation study of MGDF in 53 patients with lung cancer who were treated with carboplatin and paclitaxel. The patients were randomly assigned in blocks of 4 in a 1:3 ratio to receive either placebo or MGDF (0.03, 0.1, 0.3, 1.0, 3.0, or 5.0 µg per kilogram of body weight per day), injected subcutaneously. No other marrow-active cytokines were given.

Results In the 38 patients who received MGDF after chemotherapy, the median nadir platelet count was 188,000 per cubic millimeter (range, 68,000 to 373,000), as compared with 111,000 per cubic millimeter (range, 21,000 to 307,000) in 12 patients receiving placebo (P = 0.013). The platelet count recovered to base-line levels in 14 days in the treated patients as compared with more than 21 days in those receiving placebo (P<0.001). Among all 40 patients treated with MGDF, 1 had deep venous thrombosis and pulmonary embolism, and another had superficial thrombophlebitis.

Conclusions MGDF has potent stimulatory effects on platelet production in patients with chemotherapy-induced thrombocytopenia.

Source Information

From the Division of Hematology–Oncology, Department of Medicine, and the Winship Cancer Center, Emory University School of Medicine, Atlanta (M.F., H.O., L.H.); the UCLA School of Medicine, Los Angeles (J. Glaspy, R.F.); the Comprehensive Cancer Center and Department of Medicine, Duke University, Durham, N.C. (J.C., J. Garst); and Amgen, Inc., Thousand Oaks, Calif. (W.S., D.M., D.T.).

Address reprint requests to Dr. Fanucchi at Emory University School of Medicine, 1365 Clifton Rd., Bldg. B, Rm. B6204, Atlanta, GA 30322.

Full Text of this Article

This article has been cited by other articles:

• Kuter, D. J. (2007). New thrombopoietic growth factors. Blood 109: 4607-4616 [Abstract] [Full Text]  
• Andemariam, B., Psaila, B., Bussel, J. B. (2007). Novel Thrombopoietic Agents. ASH Education Book 2007: 106-113 [Abstract] [Full Text]  
• Li, K., Sung, R. Y. T., Huang, W. Z., Yang, M., Pong, N. H., Lee, S. M., Chan, W. Y., Zhao, H., To, M. Y., Fok, T. F., Li, C. K., Wong, Y. O., Ng, P. C. (2006). Thrombopoietin Protects Against In Vitro and In Vivo Cardiotoxicity Induced by Doxorubicin. Circulation 113: 2211-2220 [Abstract] [Full Text]  
• Kurzrock, R. (2005). Thrombopoietic Factors in Chronic Bone Marrow Failure States: The Platelet Problem Revisited. Clin. Cancer Res. 11: 1361-1367 [Abstract] [Full Text]  
• Vadhan-Raj, S., Patel, S., Bueso-Ramos, C., Folloder, J., Papadopolous, N., Burgess, A., Broemeling, L. D., Broxmeyer, H. E., Benjamin, R. S. (2003). Importance of Predosing of Recombinant Human Thrombopoietin to Reduce Chemotherapy-Induced Early Thrombocytopenia. JCO 21: 3158-3167 [Abstract] [Full Text]  
• Gunawardana, D. H., Basser, R. L., Davis, I. D., Cebon, J., Mitchell, P., Underhill, C., Kilpatrick, T. J., Reardon, K., Green, M. D., Bardy, P., Amor, P., Crump, D., Ng, S., Nation, R. L., Begley, C. G. (2003). A Phase I Study of Recombinant Human Leukemia Inhibitory Factor in Patients with Advanced Cancer. Clin. Cancer Res. 9: 2056-2065 [Abstract] [Full Text]  
• Farese, A. M., MacVittie, T. J., Roskos, L., Stead, R. B. (2003). Hematopoietic Recovery Following Autologous Bone Marrow Transplantation in a Nonhuman Primate: Effect of Variation in Treatment Schedule with PEG-rHuMGDF. Stem Cells 21: 79-89 [Abstract] [Full Text]  
• Kuter, D. J., Begley, C. G. (2002). Recombinant human thrombopoietin: basic biology and evaluation of clinical studies. Blood 100: 3457-3469 [Abstract] [Full Text]  
• Haznedaroglu, I. C., Goker, H., Turgut, M., Buyukasik, Y., Benekli, M. (2002). Thrombopoietin as a Drug: Biologic Expectations, Clinical Realities, and Future Directions. CLIN APPL THROMB HEMOST 8: 193-212 [Abstract]  
• Nomura, S., Dan, K., Hotta, T., Fujimura, K., Ikeda, Y. (2002). Effects of pegylated recombinant human megakaryocyte growth and development factor in patients with idiopathic thrombocytopenic purpura. Blood 100: 728-730 [Abstract] [Full Text]  
• Kaushansky, K., Fox, N., Lin, N. L., Liles, W. C. (2002). Lineage-specific growth factors can compensate for stem and progenitor cell deficiencies at the postprogenitor cell level: an analysis of doubly TPO- and G-CSF receptor-deficient mice. Blood 99: 3573-3578 [Abstract] [Full Text]  
• Basser, R. L., O'Flaherty, E., Green, M., Edmonds, M., Nichol, J., Menchaca, D. M., Cohen, B., Begley, C. G. (2002). Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor. Blood 99: 2599-2602 [Abstract] [Full Text]  
• Kuter, D. J., Goodnough, L. T., Romo, J., DiPersio, J., Peterson, R., Tomita, D., Sheridan, W., McCullough, J. (2001). Thrombopoietin therapy increases platelet yields in healthy platelet donors. Blood 98: 1339-1345 [Abstract] [Full Text]  
• Goodnough, L. T., Kuter, D. J., McCullough, J., Slichter, S. J., DiPersio, J., Romo, J., Peterson, R., Smith, K. J., Raife, T., Tomita, D., Armstrong, S. (2001). Prophylactic platelet transfusions from healthy apheresis platelet donors undergoing treatment with thrombopoietin. Blood 98: 1346-1351 [Abstract] [Full Text]  
• Axelrad, A. A., Eskinazi, D., Correa, P. N., Amato, D. (2000). Hypersensitivity of circulating progenitor cells to megakaryocyte growth and development factor (PEG-rHu MGDF) in essential thrombocythemia. Blood 96: 3310-3321 [Abstract] [Full Text]  
• Case, B. C., Hauck, M. L., Yeager, R. L., Simkins, A. H., de Serres, M., Schmith, V. D., Dillberger, J. E., Page, R. L. (2000). The Pharmacokinetics and Pharmacodynamics of GW395058, a Peptide Agonist of the Thrombopoietin Receptor, in the Dog, a Large-Animal Model of Chemotherapy-Induced Thrombocytopenia. Stem Cells 18: 360-365 [Abstract] [Full Text]  
• Basser, R. L., Underhill, C., Davis, I., Green, M. D., Cebon, J., Zalcberg, J., MacMillan, J., Cohen, B., Marty, J., Fox, R. M., Begley, C. G. (2000). Enhancement of Platelet Recovery After Myelosuppressive Chemotherapy by Recombinant Human Megakaryocyte Growth and Development Factor in Patients With Advanced Cancer. JCO 18: 2852-2861 [Abstract] [Full Text]  
• Harker, L. A., Roskos, L. K., Marzec, U. M., Carter, R. A., Cherry, J. K., Sundell, B., Cheung, E. N., Terry, D., Sheridan, W. (2000). Effects of megakaryocyte growth and development factor on platelet production, platelet life span, and platelet function in healthy human volunteers. Blood 95: 2514-2522 [Abstract] [Full Text]  
• Schiffer, C. A., Miller, K., Larson, R. A., Amrein, P. C., Antin, J. H., Zani, V. J., Stone, R. M. (2000). A double-blind, placebo-controlled trial of pegylated recombinant human megakaryocyte growth and development factor as an adjunct to induction and consolidation therapy for patients with acute myeloid leukemia. Blood 95: 2530-2535 [Abstract] [Full Text]  
• Vadhan-Raj, S., Verschraegen, C. F., Bueso-Ramos, C., Broxmeyer, H. E., Kudelka, A. P., Freedman, R. S., Edwards, C. L., Gershenson, D., Jones, D., Ashby, M., Kavanagh, J. J. (2000). Recombinant Human Thrombopoietin Attenuates Carboplatin-Induced Severe Thrombocytopenia and the Need for Platelet Transfusions in Patients with Gynecologic Cancer. ANN INTERN MED 132: 364-368 [Abstract] [Full Text]  
• Archimbaud, E., Ottmann, O. G., Yin, J. A. L., Lechner, K., Dombret, H., Sanz, M. A., Heil, G., Fenaux, P., Brugger, W., Barge, A., O'Brien-Ewen, C., Matcham, J., Hoelzer, D. (1999). A Randomized, Double-Blind, Placebo-Controlled Study With Pegylated Recombinant Human Megakaryocyte Growth and Development Factor (PEG-rHuMGDF) as an Adjunct to Chemotherapy for Adults With De Novo Acute Myeloid Leukemia. Blood 94: 3694-3701 [Abstract] [Full Text]  
• Heaney, M. L., Golde, D. W. (1999). Myelodysplasia. NEJM 340: 1649-1660 [Full Text]  
• Somlo, G., Sniecinski, I., ter Veer, A., Longmate, J., Knutson, G., Vuk-Pavlovic, S., Bhatia, R., Chow, W., Leong, L., Morgan, R., Margolin, K., Raschko, J., Shibata, S., Tetef, M., Yen, Y., Forman, S., Jones, D., Ashby, M., Fyfe, G., Hellmann, S., Doroshow, J. H. (1999). Recombinant Human Thrombopoietin in Combination With Granulocyte Colony-Stimulating Factor Enhances Mobilization of Peripheral Blood Progenitor Cells, Increases Peripheral Blood Platelet Concentration, and Accelerates Hematopoietic Recovery Following High-Dose Chemotherapy. Blood 93: 2798-2806 [Abstract] [Full Text]  
• Kaplan, A., Kaplan, S., Marcoe, K. F., Sauvage, L. R., Hammond, W. P. (1998). The Effect of Hematopoietic Growth Factors on Platelet Aggregability. CLIN APPL THROMB HEMOST 4: 238-242 [Abstract]  
• Nakamura, M., Toombs, C. F., Duarte, I. G., Ronson, R. S., Schmarkey, L. S., Katzmark, S. L., Robinson, J., Dillehay, D. L., Vinten-Johansen, J., Guyton, R. A. (1998). Recombinant human megakaryocyte growth and development factor attenuates postbypass thrombocytopenia. Ann. Thorac. Surg. 66: 1216-1223 [Abstract] [Full Text]  
• Kaushansky, K. (1998). Thrombopoietin. NEJM 339: 746-754 [Full Text]  
• Neelis, K. J., Visser, T. P., Dimjati, W., Thomas, G. R., Fielder, P. J., Bloedow, D., Eaton, D. L., Wagemaker, G. (1998). A Single Dose of Thrombopoietin Shortly After Myelosuppressive Total Body Irradiation Prevents Pancytopenia in Mice by Promoting Short-Term Multilineage Spleen-Repopulating Cells at the Transient Expense of Bone Marrow-Repopulating Cells. Blood 92: 1586-1597 [Abstract] [Full Text]  
• Blay, J.Y., Le Cesne, A., Mermet, C., Maugard, C., Ravaud, A., Chevreau, C., Sebban, C., Guastalla, J.-P., Biron, P., Ray-Coquard, I. (1998). A Risk Model for Thrombocytopenia Requiring Platelet Transfusion After Cytotoxic Chemotherapy. Blood 92: 405-410 [Abstract] [Full Text]  
• Harker, L. A., Marzec, U. M., Novembre, F., Sundell, I. B., Waller, E. K., Karpatkin, S., McClure, H. M., Kelly, A. B., Stead, R. B. (1998). Treatment of Thrombocytopenia in Chimpanzees Infected With Human Immunodeficiency Virus by Pegylated Recombinant Human Megakaryocyte Growth and Development Factor. Blood 91: 4427-4433 [Abstract] [Full Text]  
• Daw, N. C., Arnold, J. T., Abushullaih, B. A., Stenberg, P. E., White, M. M., Jayawardene, D., Kumar Srivastava, D., Jackson, C. W. (1998). A Single Intravenous Dose of Murine Megakaryocyte Growth and Development Factor Potently Stimulates Platelet Production, Challenging the Necessity for Daily Administration. Blood 91: 466-474 [Abstract] [Full Text]  
• Knox, S. J., Varghese, A., Khan, W., Chen, E., MacManus, M., Ray, G., Lee, K., Lamborn, K. R. (1997). A Prospective Study of Radiation Therapy-Associated Thrombocytopenia. Blood 90: 4237-4238 [Full Text]  
• Abraham, R., Basser, R. L. (1997). Megakaryocyte Growth and Development Factor: A Review of Early Clinical Studies. The Oncologist 2: 311-318 [Abstract] [Full Text]  
• Levin, J. (1997). Thrombopoietin -- Clinically Realized?. NEJM 336: 434-436 [Full Text]